Download Report

Folkets hus, Stockholm / 20–23 September 2014
Scandinavian Congress
of Rheumatology
Programme
EFFEKT
SÄKERHET
www.orencia.se
www.orenciapatient.se
Den enda biologiska
behandlingen vid
RA som selektivt
modulerar
aktiveringen
av T-celler
Tillgänglig i
både subkutan
och intravenös
beredningsform
ORENCIA® (abatacept) 125 mg injektionsvätska för subkutan injektion och 250 mg pulver till koncentrat
till infusionsvätska för intravenös infusion. Immunosuppressivt medel.
Indikation: Subkutan och intravenös beredningsform: Reumatoid artrit – ORENCIA ® i kombination med metotrexat är indicerad för
behandling av måttlig till svår aktiv reumatoid artrit hos vuxna patienter som svarat otillräckligt på tidigare behandling med en eller ﬂera
sjukdomsmodiﬁerande antireumatiska läkemedel (DMARDs), inklusive metotrexat (MTX) eller en TNF-hämmare. Vid kombinationsbehandling
med abatacept och metotrexat har reduktion av progressiv leddestruktion och förbättring av fysisk funktion påvisats. Endast intravenös
beredningsform: Polyartikulär juvenil idiopatisk artrit - ORENCIA® i kombination med metotrexat är indicerad för behandling av måttlig till svår
aktiv polyartikulär juvenil idiopatisk artrit (JIA) hos pediatriska patienter från 6 års ålder och uppåt som svarat otillräckligt på andra DMARDs
inklusive åtminstone en TNF-hämmare. ORENCIA® har inte studerats hos barn under 6 år.
Förpackning: Fyra förfyllda sprutor med 125 mg abatacept i en ml lösning. En injektionsﬂaska med 250 mg pulver och en silikonfri spruta.
Ytterligare information: ORENCIA® är receptbelagt och förmånsberättigat. För fullständig information och pris, se www.fass.se. Baserad på
produktresumé: 28 april 2014.
www.bms.se
ORE.SWE.JUL.2014
Kontraindikationer: Allvarliga okontrollerade infektioner, som sepsis och opportunistiska infektioner. Överkänslighet mot den aktiva
substansen eller mot något hjälpämne.
Contents
02.Committee
03. Welcome
04. Social programme
05. General Information
07. Congress programme at a Glance
12. Congress Programme
21. Pre-courses
24. Congress venue map
25. Exhibition Plan and Listing
26. Poster presentations
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Committee
Local organising committee
Katerina Chatzidionysiou
Jan Alvar Lindencrona
Stina Nordman
Ioannis Parodis
Anna Tjärnlund
Anna Rudin
Lars Rönnblom
Thomas Skogh
Gunnar Sturfelt
Ronald van Vollenhoven
Solveig Wållberg Jonsson
Scientific committee
Congress Secretariat
Ingrid E. Lundberg
Niels Graudal
Gerdur Gröndal
Björn Gudbjörnsson
Stefan Hagelberg
Glenn Haugeberg
Gunnar Husby
Søren Jacobsen
Meliha Kapetanovic
Dan Nordström
Anne Marie Norén
Tom Pettersson
Saedis Saevarsdottir
Kristian Stengaard Pedersen
Ulrik Tarp
Anna Tjärnlund
Carl Turesson
Rantalaiho Vappu
Caroline Åkerhielm
MCI Stockholm
Email: confirmation@mci-group.com
Phone: +46 8 5465 1500
Local scientific committee
Johan Askling
Maria Bokarewa
Hans Carlssten
Lennart Jacobsson
Lars Klareskog
Ralph Nisell
Solbritt Rantapää Dahlqvist
2
Gold Sponsors
Bristol-Myers Squibb
Celgene
Pfizer AB
UCB Pharma AB
Silver Sponsors
MSD AB
Roche AB
Bronze sponsors
AbbVie
Eli Lilly
GlaxoSmithKline
Hospira Nordic AB
Janssen-Cilag AB
Medac GmbH
Novartis
Orion Diagnostica
Sobi
Thermo Scientific
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Welcome
Welcome to the 35th Scandinavian Congress of Rheumatology
On behalf of the Board of the Scandinavian Society for Rheumatology and the
scientific committee of the Scandinavian Congress of Rheumatology, we wish
you a warm welcome to the 35th Scandinavian Congress of Rheumatology in
Stockholm September 20-23, 2014.
I
t is a great privilege to host the 35th
Scandinavian Congress of Rheumatology
which is an important meeting place for
clinicians and scientists in rheumatology
in Scandinavia to exchange knowledge,
experience and ideas and to promote Scandinavian collaborations and networking. It
is a meeting where young and established
clinicians and scientists in rheumatology
meet across the Scandinavian borders and
it is an important educational meeting for
clinicians.
With the 35th Scandinavian Congress of
Rheumatology we have a new organization as the congress, for the first time, is
organized by the Scandinavian Society for
Rheumatology in collaboration with the
national host of the congress, the Swedish
Society for Rheumatology. The Scientific
committee represents all Scandinavian
countries and also young rheumatologists.
In the 2014 congress we collaborate with
patient representatives in Nordic Rheuma
Council, with Nordic Health professionals
and with paediatric rheumatologists from
Scandinavia.
The 35th Scandinavian Congress of
www.scr2014.se
Rheumatology has a focus on areas that
are of common interest in the Scandinavian
countries and the overall topic for this
congress is Prevention and therapy in
rheumatic diseases integrating biology,
life style and outcome. One of the goals of
this congress is to promote young scientists working with rheumatology research
and to promote interdisciplinary research
in Scandinavia. There is also a focus on
education in clinical rheumatology and
rheumatology research.
The program is based on plenary lectures with update on treatment, scientific sessions with introductory talks and
selected oral presentations from submitted
abstracts, parallel workshops where interest groups present topics for discussions,
and poster presentations with organized
poster tours. We want to emphasize discussions on how we can develop Scandinavian
collaborations in the future, all to the best
for clinical care of patients with rheumatic
diseases. To strengthen the educational
part of the congress there are two one-day
pre-courses; one with a clinical focus and
one with a research focus for PhD students
3
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
in rheumatology research. We are very happy to welcome all distinguished speakers
that kindly have accepted our invitation to
the Congress. This will ensure a high scientific level of the program. We are also very
pleased to have received a high number
of excellent abstracts of which some have
been selected for oral presentations and we
will have two large poster sessions.
A warm welcome to the 35th Scandinavian
Congress of Rheumatology and we wish you
all an interesting and interactive meeting!
On behalf of the board of the Scandinavian
Society for Rheumatology, the Swedish Society for Rheumatology and of the Scientific
Committee of the Scandinavian Congress of
Rheumatology.
Stockholm in September 2014
Ingrid Lundberg
President of Scandinavian Society for
Rheumatology
Ralph Nisell
President of Swedish Society for
Rheumatology
Social programme
Welcome reception
Sunday 21 September, 18.45-21.00
City Conference Centre – Folkets Hus
Congress dinner
Monday 22 September, 18.30
”Winterviken” Alfred Nobel’s sculpture factory from 1891
Vinterviksvägen 60
117 65 Stockholm
Transportation
Boat leaves from Stadshusbron
(next to the City Hall) at 18.30 sharp!
Return by bus.
4
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
General Information
Congress venue
City Conference Centre (CCC), Folkets Hus,
which was opened in 1960, was built for
many activities with an exciting architectural design. The Congress Hall lies at the
heart of the building and can accommodate
1,400 people. Circling the Congress Hall
are another 17 conference rooms of varying
sizes, exhibition spaces and restaurants.
Folkets Hus is also home to Dansens Hus,
the primary dance scene in Stockholm, and
the nightclub le bon Palais.
City Conference Centre (CCC),
Folkets Hus
Barnhusgatan 12, 111 23 Stockholm
Coffee and lunches
Coffee and lunches will be served in the
exhibition.
Exhibition
Opening hours for the exhibition
Sunday 21 September
15.00 – 21.00
(approx.)
Monday 22 September
08.00 – 17.00
Tuesday 23 September
08.00 – 14.00
Insurance
Neither the Congress Organisers nor the
Congress Secretariat accepts any liability
for personal injuries sustained, or for loss or
damage to property belonging to congress
participants, either during or as a result of
the congress. It is strongly recommended
that you purchase an insurance policy of
www.scr2014.se
your choice as you register for the congress
and book your travel. The insurance should
be purchased in your country of origin.
Language
The official congress language is English.
There will be no simultaneous translation.
Taxi
We highly recommended that you use one
of the Taxi-company here below.
Taxi Stockholm
+46 8 15 00 00
Taxi Kurir
+46 8 30 00 00
Registration and Information
desk opening hours
The Registration desks are located outside
the Congress Hall A at Stockholm City Conference Center.
Opening hours:
Sunday 21 September
Monday 22 September
Tuesday 23 September
11.00–18.30
07.30–18.00
07.30–16.00
Internet
Complimentary Wi-Fi is provided for all
delegates and exhibitors attending the
congress.
Network: CCC
Password: Stockholm
Name badges
All participants are requested to wear their
name badge during the congress. Access
to all events and to lunch and refreshment
5
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
breaks is only possible with your personal
badge.
Posters
During the lunch there will be poster tours
where each poster will be presented during
3 minutes. For interest please sign up at
the registration desk.
Public transport
The nearest underground stations are
T-centralen (Vasagatan exit) or Hötorget
(Olof Palmes gata exit). A walk from central
station/T-centralen takes about 10 minutes,
or 5 minutes from Hötorget. For more
information please visit www.sl.se/en
tural life, Stockholm offers a wide selection of world-class museums and attractions. Most of the city’s attractions can be
reached on foot, but public transportation
is smooth and efficient.
Tourist information
For tourist information about Stockholm,
Sweden, please visit the following website:
www.visitstockholm.com
Tourist Information Centre
once in Stockholm
Speakers Ready Room’
Stockholm Visitor Centre
Kulturhuset, Sergel Torg 3,
10327 Stockholm
Tel: +46 (0) 8 508 28 508
Email: touristinfo@stockholm.se
The Speaker Ready Room is located in
Room 401. Bring your presentation on a
memory stick. Upload your presentation
at your earliest convenience, but not later
than break prior to your session.
Opening hours:
Monday to Friday
09.00–18.00
Saturday09.00–16.00
Sunday10.00–16.00
Opening hours
Sunday11.30–18.00
Monday07.30–18.00
Tuesday07.30–15.30
Stockholm
We are delighted to welcome you to Stockholm, the beautiful capital of Sweden! The
city is built on 14 islands connected by 57
bridges. The beautiful preserved buildings
of the Old Town, the greenery, the fresh air
and the proximity to water are distinctive
traits of this city. The Royal National City
Park – the first National City Park in the
world – is a green space that offers a welcome escape from the rush of the capital.
With its 750-year history and rich cul-
6
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme
at a Glance
Pre-courses
Satellite symposium
Workshops
Registration/Coffee/Lunch/Posters/Exhibition
Key note lectures
Social programme/Opening Ceremony/End of Congress
Session/Symposium
General Assembly
Saturday 20 September
11.00–13.00
Registration at Karolinska University Hospital (Pre-courses)
13.00–17.00
Nanna Svartz auditorium, Karolinska University Hospital
Pre-course, Clinical update
Rolf Luft auditorium, Karolinska University Hospital
Pre-course, Translational Science in Rheumatology
17.00
Get together with snacks, Faculty club Karolinska University Hospital
(Only for pre-course participants)
Sunday 21 September
08.30-11.30
Nanna Svartz auditorium, Karolinska University Hospital
Pre-course, Clinical update
Rolf Luft auditorium, Karolinska University Hospital
Pre-course, Translational Science in Rheumatology
11.00–18.30
Registration at Stockholm City Conference Centre – Folkets Hus
13.00–13.45
General assembly for the Scandinavian Society for Rheumatology
Room 300
14.00–15.30
Key note lectures
Chairs: Ingrid E. Lundberg, Stockholm, Sweden,
Søren Jacobsen, Copenhagen, Denmark
Room Hall A
15.30–16.00
Coffee break and Exhibition
16.00–17.30
Symposium
How to apply current knowledge compering the effectiveness of
treatments for rheumatic diseases.
Chairs: Lars Klareskog, Stockholm, Sweden,
Katerina Chatzidionysiou, Stockholm, Sweden
Room Hall A
17.45-18.45
Opening ceremony
Room Hall A
18.45-21.00
Welcome reception at City Conference Center – Folkets Hus
Room
Exhibition area
www.scr2014.se
7
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme at a Glance
Monday 22 September
07.30–18.00
Registration
08.00–09.00
SELECTIVE MODULATION OF T-CELL CO-STIMULATION:
Towards more effective use of targeted therapies
Satellite Symposium sponsored by Bristol –Myers Squibb
09.10–10.40
Parallel scientific sessions
A1. Treatment strategies for RA – today and tomorrow
Chairs: Ronald van Vollenhoven, Stockholm, Sweden,
Till Uhlig, Oslo, Norway
Room Hall A
B1. Pain in rheumatic diseases – Clinical and molecular aspects
Chairs: Jon Lampa, Stockholm, Sweden,
Berit Hagemoen Linberg, Lillehammer, Norway
Room Hall B
C1. Autoinflammatory diseases
Chairs: Tom Pettersson, Helsinki, Finland,
AnnaCarin Horne, Stockholm, Sweden
Room Hall C
10.40–11.00
Coffee break and Exhibition
11.00–12.30
Parallel scientific sessions
12.30–14.00
14.00–15.15
8
Room Hall A
A2. The pre-clinical and very early phases of rheumatoid arthritis:
Disease mechanisms and opportunities for prevention
Chairs: Solbritt Rantapää Dahlqvist, Umeå, Sweden,
Carl Turesson, Malmö, Sweden
Room Hall A
B2. Fatigue and cognitive dysfunction in rheumatic diseases
Chairs: Ann Knight, Uppsala, Sweden,
Lykke M. Ørnbjerg, Glostrup, Denmark
Room Hall B
C2. Osteoarthritis: Molecular and clinical aspects
Chairs: Ralph Nisell, Stockholm, Sweden,
Merete Hetland, Copenhagen, Denmark
Room Hall C
Lunch and poster viewing/Exhibition
Parallel workshops
Cardiovascular morbidity in rheumatic disease: What’s up?
Chairs: Solveig Wållberg Jonsson, Umeå, Sweden,
Markku Kauppi, Helsinki, Finland
Room Hall B
Predictors of disease severity and treatment response in patients
with rheumatoid arthritis
Chairs: Merete Hetland, Copenhagen, Denmark,
Alf Kastbom, Linköping, Sweden
Room Hall A
Scandinavian clinical registries for the benefit of patients and
research:
What’s on and What’s new? What can we learn from each other?
Chairs: Johan Askling, Stockholm, Sweden
Room 307
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme at a Glance
15.15–15.35
15.35–16.50
17.00–18.00
18.30
www.scr2014.se
Salivary gland biopsies in Sjögren’s syndrome- an important
diagnostic tool.
Chairs: Gunnel Nordmark, Uppsala, Sweden,
Roald Omdal, Stavanger, Norway
Room Hall C
Transition From Child To Adult With A Rheumatic Disease
Chair: Bo Magnusson, Stockholm, Sweden
Room 300
Coffee break and Exhibition
Parallel workshops
Cardiovascular prevention in rheumatic everyday practice
Chairs: Anna Södergren, Umeå, Sweden,
Kim Hörslev-Petersen, Odense, Danmark
Room Hall B
National Guidelines – How do they compare and what is the
intention of the guidelines?
Chairs: Tore Kvien, Oslo, Norway,
Ronald van Vollenhoven, Stockholm, Sweden
Room Hall A
Myositis – how we can work together in Scandinavia to
Improve patient care.
Chairs: Ingrid E. Lundberg, Stockholm Sweden,
Øyvind Molberg, Oslo, Norway
Room Hall C
Rehabilitation for patients with rheumatic diseases in at
future perspective
Chairs: Carina Thorstensson, Gothenburg, Sweden
Room 307
Aspects of axial SpA
Satellite Symposium sponsored by Pfizer.
Room: Hall A
Management of AxSpA–when and how to treat and how to
manage immunogenicity
Satellite Symposium sponsored by UCB.
Room: Hall C
Congress Dinner at Vinterviken
9
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme at a Glance
Tuesday 23 September
07.30–16.00
Registration
08.00–09.00
Facing the challenge of patient perspectives in psoriatic arthritis
Satellite Symposium sponsored by Celgene.
09.10–10.40
Parallel scientific sessions
A3. Modern anti-rheumatic treatment and current strategies for
prevention of infections
Chair: Carl Turesson, Lund, Sweden,
Anna Rudin, Gothenburg, Sweden
Room Hall A
B3. Adolescent rheumatology
Chairs: Anne Carlsson, Karlstad, Sweden,
Stefan Hagelberg, Stockholm, Sweden
Room Hall B
C3. Spondyloarthritis (Ankylosing spondylitis and psoriatic arthritis).
Chairs: Lennart Jakobsson, Göteborg, Sweden,
Björn Guðdbjörnsson, Reykjavik, Iceland
Room Hall C
10.40–11.00
Coffee break and Exhibition
11.00–12.30
Parallel scientific sessions
A4. Immunological mechanisms and clinical phenotypes
inflammatory systematic diseases
Chairs: Gunnel Nordmark, Uppsala, Sweden,
Christopher Sjöwall, Linköping, Sweden
Room Hall A
B4. Life-style factors and intervention in rheumatic diseases
Chairs: Christina Opava, Stockholm, Sweden,
Johan Isaksson, Umeå, Sweden
Room Hall B
C4. Modern imaging – clinical and molecular
Chairs: Glenn Haugeberg, Kristiansand, Norway,
Dan Nordström, Helsinki, Finland
Room Hall C
12.30–14.00
Lunch and poster viewing/Exhibition
14.00–15.30
Key note lectures
Chairs. Frank Wollheim Lund, Sweden,
Solbritt Rantapää Dahlqvist, Umeå, Sweden
15.30–16.00
End of congress
10
Room Hall A
Room Hall A
www.scr2014.se
VÄLKOMMEN TILL MONTER G4 UNDER
SCR-DAGARNA OCH TILL VÅRT SYMPOSIUM
I KONGRESSHALL C DEN 22/9, KL 17–18!
Nu me
dt
indikat re godkända
ion
reuma er inom
RA, ax tologi:
SpA oc
h PsA!
Starta resan
med målet i sikte.
Om snabb effekt och ett
tidigt svar med långsiktigt
resultat är målet, kan Cimzia®
(certolizumab pegol) vara
vägen dit1–6.
CIMZIA® (CERTOLIZUMAB PEGOL) Cimzia® 200 mg injektionsvätska, lösning, Rx, F. Farmakologisk grupp: Immunsuppressiva medel, TNF-alfa hämmare. ATC-kod: L04AB05. Indikationer: Reumatoid artrit. Cimzia, i kombination med metotrexat (MTX), är indicerat för behandling av måttlig till svår
aktiv reumatoid artrit (RA) hos vuxna patienter när behandling med sjukdomsmodifierande antireumatiska läkemedel (DMARD) inklusive metotrexat är
otillräcklig. Cimzia kan ges som monoterapi vid intolerans mot metotrexat eller om fortsatt behandling med metotrexat är olämplig. Cimzia har visats minska
progressionshastigheten av ledskador mätt med röntgen och förbättra fysiska funktioner när det ges tillsammans med metotrexat. Axial spondylartrit.
Cimzia är indicerat för behandling av vuxna patienter med svår aktiv axial spondylartrit, innefattande: Ankyloserande spondylit (AS). Vuxna med svår
aktiv ankyloserande spondylit som haft ett otillräckligt svar på, eller är intoleranta mot behandling med icke-steroida antiinflammatoriska läkemedel
(NSAID). Axial spondylartrit utan radiologiska tecken på AS. Vuxna med svår aktiv axial spondylartrit utan radiologiska tecken på AS men med objektiva
tecken på inflammation genom förhöjt CRP och/eller MR, som haft ett otillräckligt svar på, eller är intoleranta mot NSAID. Psoriasisartrit. Cimzia, i
kombination med metotrexat (MTX), är indicerat för behandling av aktiv psoriasisartrit hos vuxna patienter när behandling med sjukdomsmodifierande
antireumatiska läkemedel (DMARD) haft otillräcklig effekt. Cimzia kan ges som monoterapi vid intolerans mot metotrexat eller om fortsatt behandling med
metotrexat är olämplig. Beredningsform och förpackning: Injektionsvätska, lösning, 200 mg/ml i förfylld spruta. Varje förpackning innehåller 2 sprutor à
1 ml. Kontraindikationer: Överkänslighet mot den aktiva substansen eller mot något hjälpämne. Aktiv tuberkulos eller andra svåra infektioner såsom sepsis
eller opportunistiska infektioner. Måttlig till svår hjärtsvikt (NYHA klass III/IV). Datum för översyn av produktresumé 2014-05-16. För fullständig information,
varningsföreskrifter och aktuella priser se www.fass.se. 14-MA-0043 May 2014.
Referenser: 1. Cimzia® Produktresumé, 2014-05-16. 2. Keystone E, et al. Ann Rheum Dis 2013;0:1–7. doi:10.1136/annrheumdis-2013-203695.
3. Landewé R, et al. Ann Rheum Dis 2014;73:39–47. 4. Landewé R, et al. Arthritis Rheum 2013;65(10):S767. 5. Mease PJ, et al. Ann Rheum Dis
2014;73:48–55. 6. Mease PJ, et al. Arthritis Rheum 2013;65(Suppl. 10):S132, Abstract 312. Läs mer om alla indikationerna på www.fass.se
14-CZP-0096 aug 2014
UCB Pharma AB, Stureplan 4c, 114 35 Stockholm, tel. 040-29 49 00
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme
Sunday 21 September
11.00-18.30
Registration
13.00–13.50
General assembly for the Scandinavian Society for Rheumatology
Room: 300
14.00-15.30
Key note lectures
Chairs: Ingrid E.Lundberg, Stockholm, Sweden,
Søren Jacobsen, Copenhagen, Denmark
Room. Hall A
14.00–14.45
How to treat the individual patient with the right drug:
Personalized medicine in rheumatic diseases – Fact or Fiction?
Mathias Uhlén, Stockholm, Sweden
14.45–15.30
Getting familiar with RA: What does family history tell us?
Johan Askling, Stockholm, Sweden
15.30–16.00
Coffee break and Exhibition
16.00–17.30
How to apply current knowledge comparing the effectiveness of
treatments for rheumatic diseases.
Chairs: Lars Klareskog, Stockholm, Sweden,
Katerina Chatzidionysiou, Stockholm, Sweden
Room: Hall A
Introduction: Lars Klareskog, Stockholm, Sweden
Lessons from comparative controlled effectiveness studies of RA
and other rheumatic diseases.
Ronald van Vollenhoven, Stockholm, Sweden
Lessons from register-based studies: Treating arthritis in the
real-life individual setting.
Merete Hetland, Copenhagen, Denmark
Predicting response – are we closer to a personalized
therapeutic approach?
Tore Kvien, Oslo, Norway
Selected abstract:
Initial Infliximab is not Cost-Effective Added on to a RemissionTargeted Combination Therapy in Early Rheumatoid Arthritis.
The 2-year Results of the Randomized Clinical NEO-RACo Trial,
Vappu Rantalaiho, Lappeenranta, Finland
17.45–18.45
Opening ceremony
Room: Hall A
18.45–21.00
Welcome reception at City Conference Centre – Folkets Hus
Room
Exhibition area
12
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme
Monday 22 September
07.30–18.00
Registration
08.00–09.00
SELECTIVE MODULATION OF T-CELL CO-STIMULATION:
Towards more effective use of targeted therapies –
Satellite Symposium sponsored by Bristol – Myers Squibb
09.10–10.40
Parallel scientific sessions
09.10–10.40
A1. Treatment strategies for RA – today and tomorrow.
Chairs: Ronald van Vollenhoven, Stockholm, Sweden,
Till Uhlig, Oslo, Norway
Room: Hall A
Room: Hall A
Lessons from Fin-RACO and Neo-RACO
Vappu Rantalaiho, Tampere, Finland
Lessons from CIMESTRA and OPERA
Kim Hörslev-Pedersen, Odense, Denmark
Lessons from ARCTIC
Espen Haavardsholm, Oslo, Norway
Selected abstracts:
Impact of Physicians’ Activity and Adherence to Treat-to-Target
strategy on Outcomes in early Rheumatoid Arthritis: a
subanalysis of the Neo-RACo trail.
Laura Kuusalo, Turku, Finland
Does disease activity at start of biologic therapy influence
productivity losses in patients with RA?
Kari Johansson, Karolinska Institutet, Stockholm, Sweden
09.10–10.40
B1. Pain in rheumatic diseases – Clinical and molecular aspects.
Chairs: Jon Lampa, Stockholm, Sweden,
Berit Hagemoen Linberg, Lillehammer, Norway
Room: Hall B
Pain mechanisms in arthritis.
Camilla Svensson, Stockholm, Sweden
Pain mechanisms and coping in pediatric rheumatology.
Troels Herlin, Aarhus, Denmark
Pain in rheumatic diseases-from a clinical perspective.
Tuulikki Sokka-Isler, Jyväskylä, Finland
Selected abstracts:
The relation between pain and inflammation in early Rheumatoid
Arthritis – Long- term follow up in the Swedish population-based
EIRA and SRQ register
Maria Sandberg, Stockholm, Sweden.
Pain in Adult Idiopathic Inflammatory Myopathies
Crisitna Gonzalez-Echavarri, Vizaya, Spain.
www.scr2014.se
13
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme
09.10–10.40
C1. Autoinflammatory diseases.
Chairs: Tom Pettersson, Helsinki, Finland,
AnnaCarin Horne, Stockholm, Sweden
Room: Hall C
Autoinflammatory diseases including crystal induced
arthropathies.
Alexander So, Lausanne, Switzerland.
Genetic explanations to autoinflammatory diseases.
Alf Kastbom, Linköping, Sweden.
Inflammasome as a target of therapy.
Kari Eklund, Helsinki, Finland
10.40–11.00
Coffee break and Exhibition
11.00–12.30
Parallel scientific sessions
11.00–12.30
A2. The pre-clinical and very early phases of rheumatoid arthritis:
Disease mechanisms and opportunities for prevention.
Chairs: Solbritt Rantapää Dahlqvist, Umeå, Sweden,
Carl Turesson, Malmö, Sweden
Room: Hall A
Biomarkers and disease mechanisms in the pre-clinical phase of RA.
Heidi Kokkonen, Umeå, Sweden
The role of hormone related factors in the development of RA.
Mitra Pikwer, Eskilstuna, Sweden
Strategies for very early identification of RA.
Anette van der Helm-van Mil, Leiden, The Netherlands
Selected abstracts:
Characterization of Lung Inflammation and Identification of
Shared Citrullinated Targets in the Lungs and Joints of Early
Rheumatoid Arthritis.
Vijay Balasingh, Stockholm, Sweden
When does the female predominance in RA start – does sex
influence the risk of ACPA development.
Aase Haj-Hensvold, Stockholm, Sweden
11.00–12.30
B2. Fatigue and cognitive dysfunction in rheumatic diseases
Chairs: Ann Knight, Uppsala, Sweden,
Lykke M. Ørnbjerg, Glostrup, Denmark
Room: Hall B
Clinical manifestations of fatigue and cognitive dysfunction on SLE.
Susanne Petterson, Stockholm/Uppsala, Sweden
The impact of trauma and surgery on longterm cognitive
function, the role of inflammation.
Lars I. Eriksson, Stockholm, Sweden.
Molecular mechanisms of fatigue and cognitive dysfunction
in neuro-SLE.
Margreet Steup-Beekman, Leiden, The Netherlands
14
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme
Selected abstracts:
The association of fatigue, comorbidity burden, disease activity,
disability and gross domestic product in patients with
rheumatoid arthritis. Results from 34 countries participating in
the Quest-RA program.
Kathrine Lederballe-Grön, Copenhagen, Denmark.
Fatigue fluctuates substantially in patients with stable
rheumatoid arthritis treated with biological agents.
Ole Rintek Mades, Gentofte, Denmark.
11.00–12.30
C2. Osteoarthritis: Molecular and clinical aspects.
Chairs: Ralph Nisell, Stockholm, Sweden,
Merete Hetland, Copenhagen, Denmark
Room: Hall C
Osteoarthritis – genotypes and phenotypes.
Helgi Jonsson, Reykjavik, Iceland
Spinal osteoarthritis and pain – molecular and clinical aspects.
Eva Kosek, Stockholm, Sweden
New molecular and therapeutic opportunities in osteoarthritis.
Thomas Pap, Münster, Germany
12.30–14.00
Lunch and poster viewing/Exhibition
14.00–15.15
Parallel workshops
14.00–15.15
Cardiovascular morbidity in rheumatic disease: What’s up?
Chairs: Solveig Wållberg Jonsson, Umeå, Sweden,
Markku Kauppi, Helsinki, Finland
Room: Hall B
What’s up on vascular pathogenesis?
Ivana Hollan, Lillehammar, Norway
What’s up on thrombs and bleeding?
Aleksandra Antovic, Stockholm, Sweden
Selected abstracts:
Atherosclerosis in Systemic Lupus Erythematosus (SLE) and
Controls, -An Analysis of SLE Subgroups.
Elisabet Svenungsson, Stockholm, Sweden
Good Response on Tumour Necrosis Factors Inhibitors are
Associated with a Decreased Risk of Acute Coronary Syndromes
in Patients with Rheumatoid Arthritis.
Lotta Ljung, Umeå, Sweden
14.00–15.15
www.scr2014.se
Predictors of disease severity and treatment response in patients
with rheumatoid arthritis.
Chairs: Merete Hetland, Copenhagen, Denmark,
Alf Kastbom, Linköping, Sweden
Room: Hall A
15
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme
Topics of discussion:
• The clinical utility of imaging as a prognostic tool.
• Analyses of cartilage biomarkers in early RA.
•The rationale for taking smoking into account in treatment
decisions.
Speakers: Mikkel Østergaard, Copenhagen, Denmark, Carl Turesson,
Malmö, Sweden, Saedis Saevarsdottir, Stockholm, Sweden
14.00–15.15
Scandinavian clinical registries for the benefit of patients and
research: What’s on and What’s new? What can we learn from
each other?
Chairs: Johan Askling, Stockholm, Sweden
1.Introduction & presentation of the topic,
Johan Askling, Stockholm, Sweden
2. The Finnish perspective, Dan Nordström, Helsinki, Finland
3. The Danish perspective, TBA
4. The Norwegian perspective, Tore Kvien, Oslo, Norway
5.The Icelandic perspective, Björn Guðdbjörnsson,
Reykjavik, Iceland
6. The Swedish perspective, Sofia Ernestam, Stockholm, Sverige
7.Open discussion: progress and future strategy chaired by
Johan Askling, Stockholm, Sweden
8. Summary and conclusion, Johan Askling, Stockholm, Sweden
Room: 307
14.00–15.15
Salivary gland biopsies in Sjögren’s syndrome- an important
diagnostic tool.
Chairs: Gunnel Nordmark, Uppsala, Sweden,
Roald Omdal, Stavanger, Norway
Room: Hall C
Introductory talk: Minor salivary gland biopsies in diagnosis and
prognosis of primary Sjögren’s syndrome.
Roland Jonsson, Bergen, Norway
Topics of discussion
•Biosy sampling; procedure, number of glands and minimum
required tissue.
• Focus score assessment.
• Germinal centre assessment and prognostic value.
• Repeated biopsies in treatments studies.
Discussion partners: Elke Theander, Malmö, Sweden,
Eva Baecklund, Uppsala, Sweden
14.00–15.15
Transition from child to adult with a rheumatic disease
Chair: Bo Magnusson, Stockholm, Sweden
Karolina Larsson, Gothenburg, Sweden
15.15–15.35
Coffee break and Exhibition
15.35–16.50
Cardiovascular prevention in rheumatic everyday practice
Chairs: Anna Södergren, Umeå, Sweden,
Kim Hörslev-Petersen, Odense, Danmark
16
Room 300
Room: Hall B
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme
Cardiovascular screening of patients with rheumatic disease.
Examples from Nordic countries.
Anna Södergren, Umeå, Sweden, Anne-Grete Semb, Oslo, Norway
An electronic aid in the Swedish register.
Marika Kvarnström, Stockholm, Sweden
15.35–16.50
National Guidelines – How do they compare and what is the
intention of the guidelines?
Chairs: Tore Kvien, Oslo, Norway,
Ronald van Vollenhoven, Stockholm, Sweden
Topics of discussion:
• Strengths and weakness in rheumatology guidelines.
•Similarities and difference in guidelines from different
Nordic countries.
• The development of guidelines and major points of controversy.
Introductory talk: Challenges in international and national
guidelines, Ronald van Vollenhoven, Stockholm, Sweden
Discussion partners: Tuulikki Sokka, Finland,
Carl Turesson, Sweden, Björn Guðdbjörnsson, Iceland
Room: Hall A
15.35–16.50
Myositis - how we can work together in Scandinavia to
improve patient care.
Chairs: Ingrid E. Lundberg, Stockholm, Sweden,
Øyvind Molberg, Oslo, Norway
• Development of new classification critera for myositis
Anna Tjärnlund, Stockholm, Sweden
• How shall we treat myositis patients with ILD? Clinical experience with rituximab treatment in the anti-synthetase syndrome.
Helena Andersson, Oslo, Norway
• When should muscle biopsies be repeated.
Ingrid E. Lundberg, Stockholm, Sweden
• Myositis specific autoantibodies - test available for clinical
practice. Johan Rönnelid, Uppsala
Room: Hall C
15.35–16.50
Rehabilitation for patients with rheumatic diseases in a future
perspective.
Chairs: Carina Thorstensson, Gothenburg, Sweden
Room: 307
To illuminate the challenges and possibilities of future
rehabilitation within rheumatology.
Introduciton: Christina Opava, Stockholm, Sweden
Discussion partners: Inger Tollefsrud, Lillehammer, Norway,
Trine Seneca, Århus, Denmark, Åsa Revenäs, Stockholm. Sweden
17.00–18.00
Aspects of axial SpA
Satellite Symposium sponsored by Pfizer
Room: Hall A
17.00–18.00
Management of AxSpA-when and how to treat and how to
manage immunogenicity .Satellite Symposium sponsored by UCB
Room: Hall C
18.30
Congress dinner at Winterviken
www.scr2014.se
17
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme
Tuesday, September 23
07.30-16.00
Registration
08.00–09.00
Facing the challenge of patient perspectives in psoriatic arthritis.
Satellite Symposium sponsored by Celgene
09.10–10.40
Parallel scientific sessions
09.10–10.40
A3. Modern anti-rheumatic treatment and current strategies for
prevention of infections.
Chairs: Carl Turesson, Lund, Sweden,
Anna Rudin, Gothenburg, Sweden
Room: Hall A
Room: Hall A
Multiple determinants of risk for infections in rheumatic patients.
Adrian Richter, Berlin, Germany
Screening for infections in rheumatic diseases.
What is meaningful in clinical practice?
Søren Jacobsen, Copenhagen, Denmark
Common vaccinations and modern anti-rheumatic treatment.
What is meaningful in clinical practice?
Meliha C Kapetanovic, Lund, Sweden
Selected abstract:
The association between antibody levels before and after
7-valent pneumococcal conjugate vaccine immunization and
subsequent pneumococcal infection in arthritis patients.
Johanna Nagel, Lund, Sweden
09.10–10.40
B3. Adolescent rheumatology
Chairs: Anne Carlsson, Karlstad, Sweden,
Stefan Hagelberg, Stockholm, Sweden
Room: Hall B
Autoimmune phenotype in adolescence.
Debajit Sen, London, UK
Long-term development of juvenile arthritis regarding disease
progress and socioeconomic factors.
Helena Forsblad-d’Elia, Gothenburg, Sweden
Healthy adolescence and unhealthy behavior in adolescents with
chronic conditions.
Kristina Kelly Berg, Gothenburg, Sweden
09.10–10.40
C3. Spondyloarthritis (Ankylosing spondylitis and psoriatic
arthritis).
Chairs: Lennart Jakobsson, Göteborg, Sweden,
Björn Guðdbjörnsson, Reykjavik, Iceland
Room: Hall C
New aspects of etiology and pathogenesis of psoriasis and
psoriatic arthritis.
Mona Ståhle, Stockholm, Sweden
18
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme
Modern management of ankylosing spondylitis.
Irene van der Horst-Bruinsma, Amsterdam, The Netherlands
Diagnosis, treatment and costs of spondyloarthritis today:
Epidemiology and health economy motivates more active care
for these patients.
Emma Haglund, Halmstad/Lund, Sweden
Selected abstracts:
Long-term 52 Week Results of PALACE 1, aPhase 3, Randomized,
Controlled Trial of Apremilast,an Oral Phosphodiesterase Inhibitor, in Patients With Psoriatic Arthritis.
Adewale Adebajo, Sheffield, UK
Aortic regurgitation is common in ankylosing spondylitis and
justifies routine echocardiographic screening.
Eva Klingberg, Gothenburg, Sweden
10.40–11.00
Coffee break and Exhibition
11.00–12.30
A4. Immunological mechanisms and clinical phenotypes in inflammatory systematic diseases.
Chairs: Gunnel Nordmark, Uppsala, Sweden,
Christopher Sjöwall, Linköping, Sweden
Room: Hall A
Immunopathogenic mechanisms of systematic autoimmune disease.
Marie Wahren-Herlenius, Stockholm, Sweden
Connecting the autoimmune response to disease manifestations
in systematic inflammatory disease.
Riita Lahesmaa, Turku, Finland
Proteomic and metabolomics in the classification of SLE subsets.
Per-Johan Jakobsson, Stockholm, Sweden
Selected abstracts:
CD28null T cells are myotoxic to autologous muscle cells from
patients with polymyositis.
Andreas Fasth, Stockholm, Sweden
Interferon (IFN)-λ1/3, but not IFN-α, is a marker of poor response
to treatment in lupus nephritis.
Agneta Zickert, Stockholm, Sweden
11.00–12.30
B4. Life-style factors and intervention in rheumatic diseases.
Chairs: Christina Opava, Stockholm, Sweden,
Johan Isaksson, Umeå, Sweden
Room: Hall B
Effects of exercise, smoking, alcohol and diet (BMI) on disease
course and response to therapies in RA.
Saedis Saevarsdottir, Stockholm, Sweden
How to implement exercise programs in osteoarthritis. Methodological and psychological challenges.
Carina Thorstensson, Gothenburg, Sweden
www.scr2014.se
19
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme
Impact of societal and environmental factors on long term
outcome in rheumatoid arthritis.
Till Uhlig, Oslo, Norway
Selected abstracts:
To which extent may the familial risk of rheumatoid arthritis
be explained by established RA risk factors.
Xia Jiang, Stockholm, Sweden
Parity and severity of ACPA-positive/-negative rheumatoid
arthritis. Results from the Swedish EIRA study.
Mitra Pikwer, Lund, Sweden
11.00–12.30
C4. Modern imaging – clinical and molecular.
Chairs: Glenn Haugeberg, Kristiansand, Norway,
Dan Nordström, Helsinki, Finland
Room: Hall C
How to use imaging in SPA in clinical practice.
Mikkel Østergaard, Copenhagen, Denmark
Imaging in vasculitis with focus on PET.
Laura Pirilä, Turku, Finland
Selected abstacts:
The diagnosic utility of hand & wrist fluorescence optical
imaging in evaluating active synovitis.
Yogan Kisten, Stockholm, Sweden
Magnetic Resonance Imaging-Assessment of Early Response
to Certolizumab Pegol in Rheumatoid Arthritis.
Mikkel Østergaard, Copenhagen, Denmark
Diagnostic utility of musculoskeletal ultrasound in patients with
suspected arthritis – a probabilistic approach.
Hamed Rezaei, Stockholm, Sweden
12.30–14.00
Lunch and poster viewing/Exhibition
14.00–15.30
Keynote Lectures
Chairs: Frank Wollheim, Lund, Sweden,
Solbritt Rantapää Dahlqvist, Umeå, Sweden
Room: Hall A
Update on management of SLE
Lars Rönnblom, Uppsala, Sweden
Update on management of ANCA associated vasculitis
David Jayne, Cambridge, UK
15.30–16.00
End of congress
Invitation to the Scandinavian Congress of Rheumatology 2016
Farewell mingles
20
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Congress Programme
Saturday 20–21 September – Parallel pre-courses
Saturday 20 September
Clinical update
Nanna Svartz auditorium, Karolinska University Hospital
13.00–13.05
Welcome
Meliha C Kapetanovic, Lund, Sweden
13.05–13.50
Ultrasound in rheumatology.
Hilde Berner Hammer, Oslo, Norway
13.50–14.35
MRI analysis – to assess efficacy of treatment.
Mikkel Østergaard, Copenhagen, Denmark
14.35–14.55
Coffee break
14.55–15.40
Scleroderma clinical update
Roger Hesselstrand, Lund, Sweden
15.45–17.00
Practical demonstrations (rotation between 4 stations)
1.Basic ultrasound of joints
Hamed Rezaei, Stockholm, Sweden,
Erik af Klint, Stockholm, Sweden
2.Nailfold capillaroscopy
Roger Hesselstrand, Lund, Sweden,
Annica Nordin, Stockholm, Sweden
3.Gout and pseudogout (microscopy)
Alexander So, Lausanne, Switzerland,
Esbjörn Larsson, Stockholm, Sweden
4.Muscle strength test and muscle biopsy (video)
Maryam Dastmalchi, Stockholm, Sweden
17.00
Informal discussions with snacks
(Only for pre-course participants)
Sunday 21 September
8.30–9.15
Update on Sjögrens syndrome
Elke Theander, Malmö, Sweden
9.15–10.00
Management of crystal arthropathies
Alexander So, Lausanne, Switzerland
10.00–10.20
Coffee break
10.20–10.55
Inflammatory myopathies- update on management.
Ingrid E. Lundberg, Stockholm, Sweden
10.55–11.30
Cardiovascular risk factors in SLE- Clinical implications.
Elisabet Svenungsson, Stockholm, Sweden
Lunchbox
www.scr2014.se
21
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Saturday 20 September
Translational Science in Rheumatology
Rolf Luft auditorium, Karolinska University Hospital
13.00–13.10
Welcome and introduction.
Anna Tjärnlund, Stockholm, Sweden
13.10–14.00
T cells and adaptive immunity (and targets for therapy)
in rheumatic diseases.
Vivianne Malmström, Stockholm, Sweden
14.00–15.00
B cells in autoimmunity.
Marie Wahren-Herlenius, Stockholm, Sweden
15.00–15.20
Coffee break
15.20–16.10
Innate immunity (and targets for therapy) in rheumatic diseases.
Helena Erlandsson-Harris, Stockholm, Sweden
16.10–17.00
Genetics and genetic risk factors in rheumatic diseases.
Leonid Padyukov, Karolinska Institutet, Stockholm, Sweden
17.00
Informal discussions with snacks
(Only for pre-course participants)
08.30–09.20
Epidemiology in rheumatology research.
Lars Alfredsson, Stockholm, Sweden
09.20–10.10
Translational research in rheumatology – effects of exercise.
Ingrid E. Lundberg, Stockholm, Sweden
10.10–10.30
Coffee break
10.55–11.30
Type I IFN in rheumatic diseases.
Lars Rönnblom, Uppsala, Sweden
Sunday 21 September
Lunchbox
22
www.scr2014.se
PDE4
Please join us at our satellite symposium
FACING THE CHALLENGE
OF PATIENT PERSPECTIVES
IN PSORIATIC ARTHRITIS
AMP
Tuesday, September 23, 8.00–9.00am, Hall A
Chair and Introduction:
Prof. Tore Kvien
University of Oslo, Norway
Speakers:
Prof. Mikkel Ostergaard
University of Copenhagen, Denmark
Dr Chris Edwards
University of Southampton, UK
To discover more about the role of PDE4 in psoriasis and
psoriatic arthritis, visit us on booth G3 or visit discoverPDE4.com
cAMP
PDE4, phosphodiesterase-4; AMP, adenosine monophosphate; cAMP, cyclic AMP.
References: Houslay MD, et al. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today.
2005;10(22):1503–1519. Press NJ and Banner KH. PDE4 inhibitors – a review of the current field. In: Lawton G, Witty DR,
eds. Progress in Medicinal Chemistry. Amsterdam, The Netherlands: Elsevier; 2009:37–74. Lowes MA, et al. Pathogenesis
and therapy of psoriasis. Nature. 2007;445(7130):866–873. Veale DJ, et al. Immunopathology of psoriasis and psoriatic
arthritis. Ann Rheum Dis. 2005;64(suppl 2):ii26–ii29.
© 2014 Celgene Corporation
Date of Preparation August 2014
NS-CELG140040
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
City Conference Centre – Folkets Hus
Congress venue map
The Congress hall with 2nd and 4th floor
0m
5m
10m
203
204
201
202
28 m 2
50 m 2
28 m 2
Exhibition Hall
26 m 2
34
9 m2
33 m 2
28 m 2
m2
14 m 2
18 m 2
EXHIBITION AREA B2
EXHIBITION AREA A1
18 m 2
Poster Area
EXHIBITION AREA C4
EXHIBITION AREA C3
20 m 2
19 m 2
EXHIBITION AREA B11
5
6 m2
EX
C6
EA
2
17
m
C
AR
B4
N
B3
IO
2
IT
HISS/ELEVATOR
HOTEL
EXHIBITION AREA A9
HIB
IT
IO
N
17
A
HIB
EXHIBITION AREA B10
AR
EA
m2
A7
C
A
Poster Area
Poster Area
Poster Area
6 m2
EX
B
20 m 2
EXHIBITION AREA A8
EXHIBITION AREA C5
EXHIBITION AREA C12
REG.
DESK
19 m 2
Congress Hall A
REG.
DESK
Congress Hall B
Congress Hall C
A1
C6
BACKSTAGE
Speaker Ready Room
403
Utställningsytor
Exhibition areas
FOLKETS HUS Kongresshallen med Våning 2 och 4
The Congress Hall with Second and Forth Floor
402
401
0m
5m
10m
Ej uthyrningsbar yta
Not available area
Utställningsytor/Exhibition areas
The congress hall with 3rd and 5th floor
0m
5m
10m
300
307
GARDEROB
GARDEROB
WARDEROBE
WARDROBE
Session Room 307
Session Room 300
HISS/ELEVATOR
HOTEL
B
B5
B4
A3
C6
C
A
C7
C8
C9
A2
A1
C6
C 10
K
K/F
DM
F
M
505
504
FOLKETS HUS Kongresshallsläktaren med Våning 3 och 5
The Congress Hall Gallery with Third and Fifth Floor
503
501
502
Utställningsytor
Exhibition areas
0m
5m
10m
Ej uthyrningsbar yta
Not available area
Biomöblering/Theatre style
24
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Exhibition Plan
and Listing
0m
5m
10m
City Conference Centre
G3
B9
G: 6x2.5 meter
S: 3x2.5 meter
B: 2.5x2 meter
CATERING AREA
Folkets Hus, Stockholm
S1
G4
B10
S3
B8
B7 B6 B5
G1
G2
B11
B4 B3 B2
CATERING
A
AREA
B1
CATERING AREA
CATERING AREA
2014-06-19 version 3.2
POSTERS AREA
Company
CATERING AREA
Booth no
AbbVie
B8
Bristol-Myers Squibb
G1
Celgene
Eli Lilly
Company
CATERING AREA
MSD AB
Novartis
POSTERS
AREA
A
CA
G3
G ARE Orion Diagnostica TERING AREA
RIN
CATE
B6
Pfizer AB
B11
Booth no
S1
B10
B5
G2
Roche AB
S3POSTERS AREA
Hospira Nordic AB
B2
Sobi
B1
Janssen-Cilag AB
B7
Thermo Scientific
Medac GmbH
B9
UCB Pharma AB
GlaxoSmithKline
POSTERS AREA
Your Event Supplier
www.scr2014.se
B3 & B4
G4
REGISTRATION
AREA
25
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Poster presentations
POSTER SESSION MONDAY.
PP106 In early RA, the Multi-Biomarker
During the lunch there will be poster
tours where each poster will be presented during 3 minutes.
Disease Activity score at different timepoints is predictive of subsequent radiographic progression.
Karen Hambardzumyan, Rebecca Bolce,
Saedis Saevarsdottir, Kristina Forslind,
Ingemar Petersson, Pierre Geborek, Sofia
Ernestam, Eric Sasso, David Chernoff, Scott
Cruickshank, Ronald van Vollenhoven
Pre-clinical and early phases
of rheumatoid arthritis
PP101 The association between postmenopausal hormone therapy and the risk
of rheumatoid arthritis: results from the
Swedish EIRA study.
Cecilia Orellana, Saedis Saevarsdottir,
Lars Klareskog, Lars Alfredsson,
Camilla Bengtsson
PP102 What is the Predictive Value of a
Family History of Arthritis-Related Conditions on the Risk of Rheumatoid Arthritis,
and Does It Differ between Seropositive
and Seronegative Disease?
Thomas Frisell, Karin Hellgren, Johan Askling
PP103 Subclinical synovitis of the hands
and wrists detected by fluorescence optical
imaging and ultrasound.
Yogan Kisten, Noemi Györi, Hamed Rezaei,
Anna Karlsson, Erik af Klint, Ronald van
Vollenhoven
PP105 Dietary impact on treatment
results of MTX in patients with RA.
Cecilia Lourdudoss, Alicja Wolk,
Camilla Bengtsson, Lars Alfredsson,
Ronald van Vollenhoven
26
PP107 Using the Multi-Biomarker Disease
Activity score as a complementary inclusion criterion for clinical trials in rheumatoid arthritis may enhance recruitment.
Karen Hambardzumyan, Rebecca Bolce,
Saedis Saevarsdottir, Kristina Forslind,
Sofia Ernestam, Ingemar Petersson, Eric
Sasso, C. C. Hwang, Oscar Segurado, Pierre
Geborek, Ronald van Vollenhoven
PP108 Anti citrullinated protein antibodies (ACPA) facilitate migration of synovial
tissue-derived fibroblasts.
Meng Sun, Vijay Joshua, Aase Haj Hensvold,
Marianne Engström, Ileana R. Botusan,
Sergiu B. Catrina, Vivianne Malmström,
Anca I. Catrina, Heidi Wähämaa
PP109 Presene of Anti-Carbamylated Protein Antibodies Prior to Onset of Symptoms
of Rheumatoid Arthritis and is Associated
with Radiological Progression in Early
Rheumatoid Arthritis. Mikael Brink, Marije
K. Verheul, Johan Rönnelid, Rikard Holmdahl, Rene E.M. Toes, Lars Klareskog, Leendert
A. Trouw, Solbritt Rantapää Dahlqvist
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
OP04/PP110 Characterization of Lung
Inflammation and Identification of Shared
Citrullinated Targets in the Lungs and
Joints of Early Rheumatoid Arthritis.
Vijay Joshua, Gudrun Reynisdottir, Jimmy
Ytterberg, Marianne Engström, Anders
Eklund, Magnus Skold, Per-Johan Jakobsson, Johan Rönnelid, Vivianne Malmström,
Lars Klareskog, Johan Grunewald,
Anca I Catrina
PP111 Patterns of Isotype Distribution in
Circulating Antibodies in the Pre-clinical
Phase of Rheumatoid Arthritis and Their
Relation to Smoking.
Carl Turesson, Ulf Bergström,
Lennart Truedsson, Azita Sohrabian,
Lennart Jacobsson, Johan Rönnelid
OP05/PP112 When does the female predominance in RA start - does sex influence
the risk of ACPA development?
Aase Haj Hensvold, Thomas Frisell, Patrik
K.E. Magnusson, Johan Askling, Anca Irinel
Catrina
PP113 Autoantibodies To Citrullinated
Proteins Associate With Bone Destruction
Marker and Are Modulated By First Anti
Rheumatic Treatment In Early Rheumatoid
Arthritis.
Aase Haj Hensvold, Vijay Joshua, Wangling
Li, Michaela Larkin, Ferhan Quresh, Lena
Israelsson, Nadine Defranoux, Saedis Saevarsdottir, Anca Irinel Catrina
PP114 High Serum Cholesterol Predicts
Rheumatoid Arthritis in Women.
Carl Turesson, Ulf Bergström, Mitra Pikwer,
Jan-Åke Nilsson, Lennart Jacobsson
www.scr2014.se
PP115 High prevalence of metabolic
syndrome in early rheumatoid arthritis
patients with normal weight: a case control
study.
Raili Müller, Mart Kull, Triin Eglit, Annika
Aart, Kaja Põlluste, Margus Lember, Riina
Kallikorm
PP116 Recent infections and risk of rheumatoid arthritis –results from the population-based EIRA case-control study.
Maria Sandberg, Camilla Bengtsson, Lars
Klareskog, Lars Alfredsson, Saedis Saevars
dottir
PP117 Self-reprted Physical Activity and
the Risk of Rheumatoid Arthritis – a Prospective Study.
Sofia Hagel, Elisabet Lindqvist, Ulf Bergström, Mitra Pikwer, Jan-Åke Nilsson, Lennart TH Jacobsson, Carl Turesson
Treatment strategies for RA
PP119 Adalimumab (Humira®) normalizes
melanocortin receptor subtype 2, 3 and 4
expression in CD8+, CD14+ and CD19+ leukocyte subsets in rheumatoid arthritis.
Marlene Andersen, Michael Kruse Olesen,
Ivan Nagaev, Olga Nagaeva, Jarl Wikberg,
Lucia Mincheva-Nilsson, Grethe Neumann
Andersen and The Scandinavian Melanocortin Study Group
PP120 Methotrexate Therapy Without
Initial Dose Escalation.
Valgerdur Sigurdardottir, Tomas Husmark,
Jörgen Lysholm, Anna Svärd
27
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
PP121 Impact of tumour necrosis factor
inhibitor treatment on hand bone loss in
rheumatoid arthritis patients treated in
clinical practice. Results from the nationwide Danish DANBIO registry.
Lykke Midtbøll M. Ørnbjerg, Mikkel Østergaard, Pernille Bøyesen, Trine Jensen, Anja
Thormann, Ulrik Tarp, Wolfgang Bøhme,
Ditte Dencker, Hanne Lindegaard, Uta
Engling Poulsen, Anette Hansen, VIbeke
Ringsdal, Anette Schlemmer, Niels Graudal,
Anne Rødgaard Andersen, Jakob Espesen,
Gina Kollerup, Torben Christensen, Randi
Pelck, Bente Glintborg, Ole Madsen, Dorte
Vendelbo Jensen, Ole Majgaard, Merete
Hetland
PP122 The Tissue-Selective Estrogen
Complex Efficiently Inhibits Experimental
Arthritis and Inflammation-Induced Bone
Loss With Minimal Uterine Side Effects.
Annica Andersson, Angelina Bernardi,
Alexandra Stubelius, Merja NurkkalaKarlsson, Louise Grahnemo, Hans Carlsten,
Ulrika Islander
PP123 Methotrexate in Rheumatoid Arthritis and Psoriasis/Psoriatic Arthritis: a
Comparative Study of Hepatotoxicity.
Johanna Karlsson Sundbaum, Vendela
Berglund, Johan Back, Niklas Lehto, Irene
Vikman, Ola Rollman, Eva Baecklund
PP124 The reliability of Disease Activity
Score in 28 joints - DAS28 might be overestimated.
Rikke Asmussen Andreasen, Mark Nam van
Bui Hansen, Inger Marie Jensen Hansen
OP02/PP125 Impact of Physicians’
Activity and Adherence to Treat-to-Target
28
strategy on Outcomes in early Rheumatoid
Arthritis: a subanalysis of the Neo-RACo trial.
Laura Kuusalo, Vappu Rantalaiho, Hannu
Kautiainen, Markku Korpela, Kari Puolakka, Marjatta Leirisalo-Repo
PP126 In Rheumatoid Arthritis Patients
with Stable Low Disease Activity on
Etanercept plus Methotrexate, Continuation of Etanercept is Clinically and Radiographically Superior to Discontinuation:
Results from a Randomized, Double-Blind
Clinical Trial.
Mikkel Østergaard, Karin Franck-Larsson,
Marjatta Leirisalo-Repo, Till Uhlig, Marita
Jansson, Esbjörn Larsson, Fiona Brock,
Ronald van Vollenhoven
PP127 NORD-STAR: A multicenter, randomized, open-label, blinded-assessor, phase
4 study in patients with early rheumatoid
arthritis.
Maria Seddighzadeh and for the NORDSTAR investigators
PP128 Variations In The Interval Between
Dispensed Doses Were Observed Between
Self-Administered Tnf-Inhibitors.
Anders Berglund, Esbjörn Larsson
PP129 TNF inhibitor therapy and risk of
breast cancer recurrence in patients with
rheumatoid arthritis.
Pauline Raaschou, Thomas Frisell, Johan
Askling and The ARTIS Study group
OP03/PP130 Does disease activity at
start of biologic therapy influence productivity losses in patients with RA?
Kari Johansson, Tor Olofsson, Jonas Eriksson, Ronald van Vollenhoven, Heather
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Miller , Ingmar Peterson, Johan Askling,
Martin Neovius
Pain in rheumatic diseases –
clinical and molecular aspects
PP131 The relationship between sleep
quality and pain, mood status and clinical
symptoms in the patients with Fibromyalgia Syndrome: Preliminary results of crosssectional study.
Ayhan Bilgici, Gamze Alayli, Yasemin Ulus,
Neslihan Hezer, Omer Kuru
OP06/PP132 The relation between pain
and inflammation in early Rheumatoid
Arthritis – Long-term follow up in the
Swedish population-based EIRA and SRQ
register.
Maria Sandberg, Saedis Saevarsdottir,
Reem Altawil, Lars Alfredsson,
Lars Klareskog, Jon Lampa
PP133 Decreased risk for severe persisting pain in elderly patients with early
Rheumatoid Arthritis – Results from the
Swedish population-based EIRA and SRQ
register.
Maria Sandberg, Reem Altawil,
Lars Alfredsson, Lars Klareskog,
Saedis Saevarsdottir, Jon Lampa
PP134 Effect of a Thin Dynamic Insole on
clinical and ultrasound findings in a pilot
study.
Sara Lind, Patric Nordström, Yogan Kisten,
Adrian Levitsky, Nancy Vivar, Ronald van
Vollenhoven
OP07/PP136 Pain in Adult Idiopathic
Inflammatory Myopathies.
Cristina Gonzalez-Echavarri,
Ingrid Lundberg, Helene Alexanderson
PP137 Remaining pain despite inflammation control in rheumatoid arthritis – longterm increased risk for widespread pain
and fatigue.
Maria E. Sandberg, Saedis Saevarsdottir,
Reem Altawil, Lars Klareskog, Lars Alfredsson, Jon Lampa and The EIRA working
group
Osteoarthritis- molecular and
clinical aspects
PP138 Heparin-binding Protein (HBP)
in Joint Fluid Distinguishes Rheumatoid
Arthritis from Osteoarthritis.
Adam Linder, Anders Gülfe, Johanna Nagel
PP139 Bone mineral density in postmenopausal women with hip osteoarthritis.
Nataliia Grygorieva, Vladyslav Povoroznyuk, Svytoslava Krochak
Pain and Walking Ability in Rheumatoid
Arthritis.
Berit Hagemoen Linberg, Anne Marit
Mengshoel
Fatigue and cognitive dysfunction in rheumatic
diseases
PP135 Kaltenborn’s manual mobilization
PP140 The Prevalence of Pernicious Anae-
method for pain relief in RA hand joints:
mia, Cobalamine and Folic Acid Deficiency
www.scr2014.se
29
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
among Patients newly diagnosed with
Rheumatoid Arthritis. A Descriptive Cross
Sectional Study.
Niels Lomborg, Søren Andreas Just , Rannveig Gildberg-Mortensen , Rikke Asmussen Andreasen, Inger Marie Jensen Hansen
OP09/PP141 Fatigue fluctuates substantially in patients with stable rheumatoid
arthritis treated with biological agents.
Emilie Lund Esmose, René Cordtz, Ole
Rintek Madsen
PP142 Fatigue correlates with Mental
Health and Quality of Life in Primary
Sjögren’s Syndrome.
Rezvan Kiani, Lilian Vasaitis, Anncarin
Svanberg, Gunnel Nordmark
OP08/PP143 The association of fatigue,
comorbidity burden, disease activity,
disability and gross domestic product in
patients with rheumatoid arthritis. Results
from 34 countries participating in the
Quest-RA program.
Kathrine Lederballe Grøn, Lykke Ørnbjerg,
Merete Hetland, Tuulikki Sokka and QuestRA investigators
PP144 Fatigue in adult idiopathic inflammatory myopathies.
Åsa Björklund, Ingrid Lundberg, Helene
Alexanderson
Comorbidities and rheumatic
diseases
PP146 Does Rheumatoid arthritis protect
against multiple sclerosis, and if so, when?
A population-based study.
30
Elizabeth Arkema, Thomas Frisell, Tomas
Olsson, Johan Askling
PP147 Dietary nutrients and carotid atherosclerosis in SLE patients.
Cecilia Lourdudoss, Ronald van Vollenhoven, Johan Frostegård
PP148 Heart involvement in systemic
sclerosis patients and mice models.
Paulius Venalis, Gábor Kumánovics,
Hendrik Schulze-Koops, Alfiya Distler,
Clara Dees, Pawel Zerr, Katrin PalumboZerr, László Czirják, Zygmunt Mackevic,
Ingrid E. Lundberg, Oliver Distler, Georg
Schett, Jörg H.W. Distler
OP12/PP149 The association between
antibody levels before and after 7-valent
pneumococcal conjugate vaccine immunization and subsequent pneumococcal
infection in arthritis patients.
Johanna Nagel, Tore Saxne, Pierre Geborek,
Göran Jönsson, Martin Englund, Ingemar
F. Petersson, Jan-Åke Nilsson, Lennart
Truedsson, Meliha C. Kapetanovic
PP150 Expression of HMGB1 and Its Receptors in Hearts of Patients with Coronary
Artery Disease with or without Inflammatory Rheumatic Disease: A Biopsy Study.
Mei Zong, Ivana Hollan, Huiyuan Xiao, Cecilia Wick, Helena Harris, Ingrid Lundberg
OP10/PP151 Atherosclerosis in Systemic
Lupus Erythematosus (SLE) and Controls,
-An Analysis of SLE Subgroups.
Johanna Gustafsson, Kerstin JensenUrstad, Marie Herlitz-Lindberg, Sonia
Möller, Susanne Pettersson, Iva Gunnars-
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
son, Anders Larsson, Elisabet Svenungsson
PP152 A comparison between patients
with rheumatoid arthritis in the western
part of Sweden with or without treatment
with biologics.
Karin Bengtsson, Mats Dehlin, Elisabeth
Hilme, Göran Kvist, Barbro Rydberg, Tomas
Torstenson, Anna Lindhé, Susanna M
Wallerstedt, Helena Forsblad-dÉlia
PP153 Frequency of Metabolic syndrome
in Patients with Gout: A retrospective
cross-sectional study.
Melanie Morillon,
Inger Marie Jensen Hansen
PP154 Increased incidence of low-energy
fractures in RA patients from northern
Sweden.
Solbritt Rantapää Dahlqvist,
Kristina Wiberg, Ulrika Bergström,
Marie-Louise Öhman
PP155 The value of Quantiferon TB Gold
In-Tube test in identification of latent
tuberculosis in rheumatic patients before
treatment with TNF-a blockers in Vilnius
University Hospital Santariskiu Clinics.
Inesa Arstikyte, Irena Butrimiene,
Rolandas Zablockis, Algirdas Venalis
OP11/PP156 Good Response on Tumour
Necrosis Factor Inhibitors are Associated
with a Decreased Risk of Acute Coronary
Syndromes in Patients with Rheumatoid
Arthritis.
Lotta Ljung, Lennart Jacobsson, Solbritt
Rantapää Dahlqvist, Johan Askling and
ARTIS Study Group
www.scr2014.se
PP157 Prevalence of comorbidities in
rheumatoid arthritis. Does gross domestic
product matter? Results from 34 countries
in the quest-ra program.
Kathrine Lederballe Grøn, Lykke Ørnbjerg, Merete Hetland, Tuulikki Sokka and
QUEST-RA investigators
Autoinflammatory diseases –
clinical and molecular aspects
PP158 Gout – an old disease in a new
phenotype.
Michael Fiene, Beate Fiene, Verena Karnebeck
Vasculitis
PP159 Inflammation, Vitamin D and Bone
Mineral Density in patients presenting
with Giant Cell Vasculitis and/or Polymyalgia Rheumatica.
Søren A. Just, Rikke Asmussen Andreasen,
Rannveig Gildberg-Mortensen, Niels Lomborg,
Petur Weihe, Inger Marie Jensen Hansen
PP160 Carcinoma of the prostate, RS3PE
and Polymyalgia Rheumatica. A case study.
Rannveig A. Gildberg-Mortensen, Lars Kjær
Nielsen, Erik Øster-Jørgensen, Søren Hess,
Inger Marie Jensen Hansen
PP161 Clinical and laboratory characteristics associated with visual complications
in patients with biopsy-proven giant cell
arteritis.
Muna Saleh, Carl Turesson, Martin Englund,
Peter A Merkel, Aladdin J Mohammad
31
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
PP162 Low CD4/CD8 Ratio is Associated
with Lower Immunoglobulin Levels in
Granulomatosis with Polyangiitis Patients
Receiving Rituximab.
Emilio Besada, Johannes C Nossent
PP163 Chronic Nasal Carriage of Staphylococcus Aureus in Granulomatosis with
Polyangiitis Patients Receiving Rituximab
Maintenance: Friend or Foe?
Emilio Besada, Wenche Koldingsnes,
Johannes C Nossent
PP164 Late onset neutropenia in ANCA-associated vasculitis after rituximab treatment
Ann Knight, Annette Bruchfeld,
Iva Gunnarsson
PP165 The use of positron emission
tomography (PET) imaging as diagnostic
procedure when vasculitis is suspected.
Soile Salomäki, Kirsi Taimen, Johanna Silvola,
Jukka Kemppainen, Ulla Hohenthal, Antti
Saraste, Anne Roivainen, Laura Pirilä
PP166 The Impact of Clinical Features
and Corticosteroids on Biopsy Findings in
Giant Cell Arteritis.
Karin Jakobsson, Lennart Jacobsson, Aladdin Mohammad, Jan-Åke Nilsson, Kenneth
Warrington, Eric Matteson, Carl Turesson
PP167 The diagnostic performance of
FDG PET-CT in patients with polymyalgia
rheumatica and giant cell arteritis.
Rannveig A. Gildberg-Mortensen, Erik
Øster-Jørgensen, Søren Hess, Inger Marie
Jensen Hansen
32
Molecular aspects on pathogenesis in arthritis/bone
destruction
PP168 Cathepsin s and cathepsin l in
serum and synovial fluid in rheumatoid
arthritis with and without autoantibodies.
Tomas Weitoft, Anders Larsson, Vivek
Manivel, Jörgen Lysholm, Ann Knight,
Johan Rönnelid
PP169 Chemokine-Mediated Regulation
of Th17-Cell Migration as a Novel Mechanism for Estrogen-Induced Amelioration of
Experimental Arthritis.
Annica Andersson, Alexandra Stubelius,
Merja Nurkkala-Karlsson, Cecilia Engdahl,
Malin Erlandsson, Louise Grahnemo,
Marie K Lagerquist, Ulrika Islander
PP170 CD25+CD39+ Tregs are enriched at
the site of inflammation of patients with
rheumatoid arthritis and impaired in suppressing IL-17A secretion.
Jessica Herrath, Karine Chemin,
Inka Albrecht, Anca I. Catrina,
Vivianne Malmstrom
PP171 Alternatively Spliced Isoform Expression of PTPN2 in Rheumatoid Arthritis.
Miranda Houtman, Klementy Shchetynsky,
Leonid Padyukov
PP172 Lasofoxifene and Bazedoxifene
Suppress Bone Marrow B cell Development
Differently than 17β-estradiol and Do Not
Increase Peripheral B cell Activity.
Angelina Bernardi, Annica Andersson,
Louise Grahnemo, Merja Nurkkala Karlsson, Hans Carlsten, Ulrika Islander
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
PP173 B-cell responses to de novo identified citrullinated fibrinogen peptides are
associated with PTPN22 risk allele.
Vijay Joshua, Loes Schobers, Lena Israelsson,
Monika Hansson, Johan Rönnelid,
Anca I Catrina, Ger JM Pruijn,
Vivianne Malmström
PP174 Osteoclastogenesis Is Enhanced By
Anti-Citrullinated Proteins Antibodies In
Rheumatoid Arthritis.
Akilan Krishnamurthy, Vijay Joshua,
Heidi Wähämaa, Nataliya Tarasova, Catia
Cerqueira, Elena Ossipova, Nancy Vivar,
Khaled Amara, Karin Lundberg, Vivianne
Malmström, Per-Johan Jakobsson, Georg
Schett, Jimmy Ytterberg, Anca Catrina
PP175 HIF-2 α dependent RANKL induction and osteoclastogenesis is augmented
by inflammatory cytokines.
Shankar Revu, Akilan Krishnamurthy,
Xiaowei Zheng, Vivekananda Gupta Sunkari,
Ileana Ruxandra Botusan, Marina Korotkova, Sergiu-Bogdan Catrina, Anca Catrina
PP176 Identification of a new citrullinated collagen-type II T cell epitope in HLADRB1*1001 positive-reumatoid arthritis
patients.
Karine Chemin, Eddie James, Jessica Herrath, Inka Albrecht, Catrina Anca, Leonid
Padyukov, Lars Rönnblom, Lars Klareskog,
Vivianne Malmström
PP177 Anti TNF therapy with adalimumab
restores the bone metabolism balance
through a dual mechanism in rheumatoid
arthritis.
Akilan Krishnamurthy, Shankar Revu,
Aase Hensvold, Petra Neregård, Marianne
www.scr2014.se
Engström, Erik af Klint, Dimitrios Makrygiannakis, Anca Catrina
PP178 Differences in the Auto-reactive Tcell Pool when Restricted by the Highly Related Rheumatoid Arthritis Associated HLADRB1 Alleles *04:01, *04:04 and *01:01.
Charlotta Sandin, Christina Gerstner,
Hannes Uchtenhagen, Eddie James,
Jennifer Pieper, Mary Rieck, Adnane
Achour, Jane H Buckner, Tatiana Sandalova,
Vivianne Malmström
PP179 Endogenous b cell-targeted antigen
expression induces tolerance to collagen
type ii arthritis in Mice.
Sofia Andersson, Tove Eneljung, Sara
Tengvall, Lill Mårtensson, Kenth Gustafsson, Holmdahl Rikard, Jan Kihlberg, Anna
Stern, Pernilla Jirholt, Inger Gjertsson
POSTER SESSION TUESDAY
During the lunch there will be poster
tours where each poster will be presented during 3 minutes.
Comparative effectiveness
of treatments for rheumatic
diseases
PP201 Baricitinib, an Oral Janus Kinase
Inhibitor, in the Treatment of Rheumatoid
Arthritis: Safety and Efficacy in an OpenLabel, Long-Term Extension Study1.
Peter Taylor, Mark Genovese, Ed Keystone,
Douglas Schlichting, Scott Beattie,
William Macias, Jonas Lundmark
(presenter only)
33
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
PP202 In early RA patients with non-
PP207 How good is the coverage and how
response to methotrexate monotherapy the
change in Multibiomarker Disease Activity
score is differentially associated with subsequent response to non-biological versus
biological therapy.
Karen Hambardzumyan, Rebecca Bolce,
Saedis Saevarsdottir, Kristina Forslind,
Ingemar Petersson, Pierre Geborek, Sofia
Ernestam, Eric Sasso, David Chernoff, Scott
Cruickshank, Ronald van Vollenhoven
accurate are data in the Swedish biologics
register (Artis).
Hjalmar Wadstrom, Johan Askling,
Martin Neovius, Jonas Eriksson
to Support Health Economics Research in
Rheumatic Diseases. Heather Miller
PP208 Drug survival in patients receiving
golimumab treatment 2010-2013. Results
from the swedish rheumatology quality
register.
Saedis Saevarsdottir, Michele Santacatterina, Leszek Stawiarz, Carl Turesson,
Helena Forsblad-d’Elia, Lennart Jacobsson,
Staffan Lindblad and Swedish Rheumatology Quality Register
PP204 Costs in relation to disability,
OP01/PP209 Initial Infliximab is not
disease activity and health-related quality
of life in rheumatoid arthritis.
Johan A. Karlsson, Jonas Eriksson, Jan-Åke
Nilsson, Tor Olofsson, Lars-Erik Kristensen,
Martin Neovius, Pierre Geborek
Cost-Effective Added on to a RemissionTargeted Combination Therapy in Early
Rheumatoid Arthritis. The 2-year Results of
the Randomized Clinical NEO-RACo Trial.
Vappu Rantalaiho, Janne Martikainen,
Hannu Kautiainen, Kari Puolakka,
Marjatta Leirisalo-Repo and the NEO-RACo
Study Group
PP203 Utilization of Nordic Registries
PP205 Patient Characteristics in the Prospective International Register of Biologics
in SLE (IRBIS-II): year one data.
Melinda Mild, Daniel J Wallace, Ann
E Clarke, Sasha R Bernatsky, Christine
Peschken, Soren Jacobsen, Guillermo RuizIrastorza, John G Hanly, Diane Kamen,
Rosalind Ramsey-Goldman, Michelle A
Petri, Paul Fortin, Ronald van Vollenhoven
and the SLICC group
PP206 Sick leave and disability pension
in relation to first initiation of biologic
therapy across indications: a nationwide
cohort study.
Jonas Eriksson, Lennart Jacobsson,
Lars-Erik Kristensen, Johan Askling,
Martin Neovius
34
Spondyloarthritis – pathogenesis and management
PP210 Effect of Secukinumab on psoriasis symptoms and physical functioning
compared with placebo and etanercept in
subjects with moderate-to-severe plaque
psoriasis and concomitant psoriatic
arthritis: a subanalysis from the phase 3
FIXTURE study.
B Sigurgeirsson, AB Gottlieb, RG Langley,
S Philipp, RLM Martin, C Papavassilis, S
Mpofu
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
PP211 A Number of Autoimmunity-related
Gene Polymorphisms are not Associated
with Ankylosing Spondylitis in Latvian
Population.
Julija Zepa, Laila Zepa, Inita Bulina,
Anna Sarbantovica, Vladimirs Lavrentjevs,
Evita Sikora, Janis Arajs, Aivars Lejnieks,
Daina Andersone, Janis Klovins,
Liene Nikitina-Zake
PP212 A rare case of Potts Disease in
Denmark.
Azra Osmanagic, Jacob Christian Bang,
Rasa Ramoskiene,
Inger Marie Jensen Hansen
PP213 Comparison of Sociodemographic
characteristics, Clinical Variables and
Depression in Patients with Psoriasis and
Psoriatic Arthritis.
Omer Kuru, Sertac Ketenci, Ayhan Bilgici,
Gamze Alayli, Yesim Akyol, Yasemin Ulus
OP17/PP214 Long-term 52-Week Results
of PALACE 1, a Phase 3, Randomized,
Controlled Trial of Apremilast, an Oral
Phosphodiesterase Inhibitor, in Patients
With Psoriatic Arthritis.
Adewale Adebajo, Juan Gomez-Reino,
Philip Mease, Jürgen Wollenhaupt,
ChiaChi Hu, Kamal Shah, Randall Stevens,
Arthur Kavanaugh
PP215 Long-term 52-Week Results
of PALACE 3, a Phase 3, Randomized,
Controlled Trial of Apremilast, an Oral
Phosphodiesterase 4 Inhibitor, in Patients
With Psoriatic Arthritis and Current Skin
Involvement. Christopher Edwards,
Francisco Blanco, Jeffrey Crowley,
ChiaChi Hu, Randall Stevens, Charles Birbara
www.scr2014.se
PP216 Long-term Safet and Tolerability
of Apremilast, an Oral Phosphodiesterase 4
Inhibitor, in Patients With Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3,
Randomized, Controlled Trials.
Adewale Adebajo, Philip Mease, Arthur
Kavanaugh, Dafna Gladman, Juan GomezReino, Jürgen Wollenhaupt, Maurizio
Cutolo, Georg Schett, Eric Lespessailles,
Kamal Shah, ChiaChi Hu, Randall Stevens,
Christopher Edwards, Charles Birbara
PP217 Inflammatory Bowel Disease associated arthropathy: characteristics of the
disease and validity of diagnoses based on
ICD-coding in Sweden.
Panagiota Drivelegka, Nikolaos Papachrysos, Ingemar Petterson, Ann Bremander,
Lennart Jacobsson
PP218 Disease severity as measured by
PROMs or need for second line treatment
in Inflammatory Bowel Disease associated
arthropathy: comparison to other Spondyloarthritis subgroups.
Panagiota Drivelegka, Nikolaos Papachrysos, Ingemar Petersson, Ann Bremander,
Lennart Jacobsson
PP219 Comparison of nonradiographic
axial spondyloarthritis and ankylosing
spondylitis patients – baseline characteristics and development of clinical variables
during three years of anti-tnf therapy in
clinical practice.
Johan A. Karlsson, Meliha C Kapetanovic,
Ingemar F Petersson, Pierre Geborek, LarsErik Kristensen
PP220 The Use of the mSASSS Method by
Different Specialists.
35
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Julija Zepa, Inita Bulina, Vladimirs
Lavrentjevs, Santa Kadike, Liene NikitinaZake, Aivars Lejnieks, Daina Andersone
PP221 Hyaluronan is related to TNF in
patients with Ankylosing Spondylitis.
Daniel Hedqvist, Urban Hellman, Lan Do,
Björn Sundström, Solveig Wållberg-Jonsson
OP18/PP222 Aortic regurgitation is
common in ankylosing spondylitis and justifies routine echocardiographic screening.
Eva Klingberg, Bente Grüner Sveälv,
Meta Scharin Täng , Odd Bech-Hanssen,
Lennart Bergfeldt, Helena Forsblad-d’Elia
Modern imaging – clinical
and molecular
OP20/PP223 Magnetic Resonance
Imaging-Assessment of Early Response to
Certolizumab Pegol in Rheumatoid Arthritis: a Randomized, Double-Blind, PlaceboControlled Phase IIIb Study Applying
Magnetic Resonance Imaging at Weeks 0, 1,
2, 4, 8 and 16.
Mikkel Østergaard, Lennart Jacobsson,
Christopher Schaufelberger, Michael SejerHansen, Johannes Bijlsma, Anna Dudek,
Maria Rell-Bakalarska, Fabienne Staelens,
Robert Haake, Britt Sundman-Engberg,
Henning Bliddal
PP224 Trabecular bone score in patients
with rheumatoid arthritis.
Vladyslav Povoroznyuk, Tetiana Karasevska, Roksolana Povoroznyuk, B. AubryRozier, Didier Hans
36
PP225 Influence of glucocorticoids on
trabecular bone score in patients with
rheumatoid arthritis.
Vladyslav Povoroznyuk, Tetiana Karasevska, B. Aubry-Rozier, Nataliia Dzerovych,
Roksolana Povoroznyuk, Didier Hans
OP19/PP226 The diagnostic utility of
hand & wrist fluorescence optical imaging
in evaluating active synovitis.
Yogan Kisten &, Noemi Györi, Hamed
Rezaei, Anna Karlsson, Erik af Klint, Ronald van Vollenhoven
PP227 Dual Energy CT (DECT) imaging of
tophi and monosodium urate deposits in a
patient with longstanding anorexia nervosa.
Jóhan Petur Weihe, Melanie B. Morillon,
Jess Lambrechtsen,
Inger Marie Jensen Hansen
OP21/PP228 Diagnostic utility of
musculoskeletal ultrasound in patients
with suspected arthritis – a probabilistic
approach.
Hamed Rezaei, Søren Torp-Pedersen,
Erik af Klint, Yogan Kisten, Noémi Györi,
Ronald F. van Vollenhoven
PP229 Wholebody and conventional
magnetic resonance imaging for assessing
inflammation and structural damage in
psoriatic arthritis and axial spondyloarthritis.
René Panduro P. Poggenborg, Susanne Juhl
Pedersen, Iris Eshed, Inge Juul Sørensen,
Ole Rintek Madsen, Jakob M Møller, Mikkel
Østergaard and Copenhagen Center for
Arthritis Research
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
PP230 Mri of the hand and wrist as a
tool for detection of joint damage in early
rheumatoid
Kristina Forslind, Björn Svensson
Life-style factors and intervention in rheumatic diseases
PP231 Comparison of a 12-Week Partly
Supervised Exercise Programme Versus a
Self-administered Exercise Programme for
Patients With Newly Diagnosed Rheumatoid Arthritis.
Trine Seneca, Ellen Margrethe Hauge,
Thomas Maribo
OP15/PP232 To which extent may the
familial risk of rheumatoid arthritis be
explained by established RA risk factors?
Xia Jiang, Thomas Frisell, Johan Askling,
Lars Klareskog, Lars Alfredsson,
Henrik Källberg
OP16/PP233 Parity and severity of ACPA-positive/-negative rheumatoid arthritis.
Results from the Swedish EIRA study.
Mitra Pikwer, Cecilia Orellana, Henrik
Källberg, Andreas Pikwer, Carl Turesson,
Lars Klareskog, Lars Alfredsson, Saedis
Saevarsdottir, Camilla Bengtsson
PP234 Screening and Simple Counselling
Affected Traditional Cardiovascular Risk
Factors in Patients with Early Rheumatoid
Arthritis.
Johan Isaksson, Solveig Wållberg-Jonsson,
Gerd-Marie Alenius, Anna Södergren
PP235 Smoking functions as a negative
regulator of IGF-1 levels and adipokine net-
www.scr2014.se
work in patients with rheumatoid arthritis.
Maria Bokarewa, Malin Erlandsson, Roberto Doria Medina, Sofia Töyrä Silfverswärd,
Andreea Ioan-Facsinay
PP236 An outsourced health-enhancing
physical activity program for people with
rheumatoid arthritis. Feasibility, adherence
and response The PARA 2010 study.
Birgitta Nordgren, Cecilia Fridén,
Ingrid Demmelmaier, Gunnar Bergström,
Ingrid Lundberg, Alyssa Dufour,
Christina Opava and The PARA study
group
PP237 Smoking cessation in patients
with rheumatic disease.
Marie-Louise Karlsson, Susanne Pettersson,
Ingrid Lundberg
PP238 Effect of exercise and life style
interventions on an outpatient rehabilitation program for patients with OA in hip(s)
or knee(s).
Inger Tollefsrud, Ellen Askmann
PP239 Development of a Web and Mobile
Application to Support Physical Activity
in Rheumatoid Arthritis: Results from the
Second Step of a Co-design Process.
Åsa Revenäs, Christina H. Opava,
Ingrid Demmelmaier, Christina Keller,
Pernilla Åsenlöf
PP240 The Swedish Exercise Self-Efficacy
Scale (ESES-S): reliability and validity in a
rheumatoid arthritis population.
Thomas Nessen, Ingrid Demmelmaier,
Birgitta Nordgren, Christina H Opava
37
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
PP241 Serum 25-hydroxyvitaminD below
75 nmol/L in 75% of healthy Swedish adults
during 75% of the year.
Eva Klingberg, Göran Oleröd, Jan Konar,
Max Petzold, Ola Hammarsten
PP246 Comparison of Lymphomas in Pri-
Inflammatory systemic
diseases – immunological
mechanisms and clinical
phenotypes
PP247 Sex ratio of offspring born to
PP242 Detection of antinuclear antibod-
PP248 Initial symptoms of sarcoidosis
ies – a comparison of indirect immunefluorescence on HEp-2 cells and fluoroenzymeimmunoassay (EliA CTD screen,
Thermo Fisher).
Lone Nørgård Troelsen, Søren Jacobsen
can be neurological – A Case Story.
Jon Henriksen, Karen Ege Olsen, Rasa Ramoskiene, Inger Marie Jensen Hansen
OP13/PP243 CD28null T cells are
myotoxic to autologous muscle cells from
patients with polymyositis.
Jayesh Pandya, Paulius Venalis, Lubna
Al-Khalili, Mohammad Hossain, Vanessa
Stache, Ingrid E Lundberg, Vivianne Malmström, Andreas Fasth
PP244 Autoantibodies against high mobility group box protein-1 in systemic lupus
erythematosus: association with disease
activity and other antinuclear antibodies.
Christopher Sjöwall, Lina Wirestam, Jonas
Wetterö, Lars Ottosson, Erik Sundberg,
Thomas Skogh, Hanna Schierbeck
PP245 Development of IgG Antibodies to
Streptavidin may Explain a Case of False
Positive Autoantibody Screening Test for
Connective Tissue Disease (CTD).
Pernille Hurup Duhn, Thor Skovsted, Bjarne
Kristensen, Henning Locht
38
mary and Secondary Sjögren’s Syndrome.
Lilian Vasaitis, Gunnel Nordmark, Johan
Askling, Karin Ekstrom.Smedby, Carin
Backlin, Christer Sundström, Elke Theander, Eva Baecklund
women with lupus.
Elizabeth Arkema, Jane Salmon,
Julia F Simard
PP249 Maternal and Fetal Outcomes in
Pregnant Systemic Lupus Erythematosus
Patients: An Incident Cohort from a Stable
Referral Population Followed During
1990–2010.
Iris Marie Jakobsen, Rikke Bek Helmig,
Kristian Stengaard-Pedersen
PP250 Angiogenesis Factors – Markers
for Paraneoplastic Rheumatic Syndromes.
Ieva Talijûniené, Paulius Venalis, Jolanta
Dadoniené, Algirdas Venalis, Jorg Distler,
Ingrid Lundberg, Rita Rugiené
PP251 High serum levels of IFN-λ1/3
and IFN-α characterize two separate subgroups among SLE patients.
Vilija Oke, Johanna Gustafsson, Susanna
Brauner, Agneta Zickert, Iva Gunnarsson,
Elisabet Svenungsson
PP252 An NFKB1 Gene Promoter
Polymorphism is Associated with Primary
Sjögren’s Syndrome.
www.scr2014.se
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Gunnel Nordmark, Lilian Vasaitis, Elke
Theander, Marika Kvarnström, Svein Joar
Johnsen, Johan G Brun, Malin V Jonsson,
Christopher Sjöwall, Helena Forsbladd’Elia, Marie Wahren-Herlenius, Roald
Omdal, Roland Jonsson, Maija-Leena
Eloranta, Per Eriksson
OP14/PP253 Interferon (IFN)-λ1/3, but
not IFN-α, is a marker of poor response to
treatment in lupus nephritis.
Agneta Zickert, Vilija Oke, Ioannis Parodis,
Elisabet Svenungsson, Iva Gunnarsson
PP254 Work ability in patients with polymyositis and dermatomyositis: an explorative and descriptive study.
Malin Regardt, Elisabet Welin Henriksson,
Jan Sandqvist, ingrid Lundberg,
Marie-Louise Schult
PP255 Activated T cells Enhance the
Interferon-α Production by Plasmacytoid
Dendritic Cells Stimulated by RNA containing Immune Complexes.
Dag Leonard, Maija-Leena Eloranta, Niklas
Hagberg, Olof Berggren, Karolina Tandre,
Gunnar Alm, Lars Rönnblom
PP256 Indirect Immunoflourescence On
Hep-2 Cells Versus ELIA CTD Screen For
The Detection Of Anti-Nuclear Antibodies.
Trine Korsholm, Anne Troldborg,
Berit Dalsgaard Nielsen
PP257 Increased levels of thrombin activatable fibrinolysis inhibitor correlate with
complement activation in patients with the
antiphospholipid syndrome.
Aleksandra Antovic, Anna Vikerfors,
Elisabet Svenungsson
www.scr2014.se
PP258 T cell subsets profile in peripheral
blood from idiopathic inflammatory myositis patients.
Fabricio Espinosa, Karina De Anda,
Diana Gomez
PP259 Decreased disease activity and
corticosteroid usage and no renal flares
during belimumab treatment in patients
with Systemic Lupus Erythematosus.
Ioannis Parodis, Elisabet Svenungsson,
Magnus Axelsson, Iva Gunnarsson
PP260 Microcirculation and macrovascular disease in systemic sclerosis – a
nailfold capillary study.
Annica Nordin, Lena Björnådal,
Evangelia Roubi, Kerstin Jensen-Urstad,
Elisabet Svenungsson
PP261 Effect of Single-Nucleotide Polymorphisms on Type I Interferon Production
by Plasmacytoid Dendritic Cells Stimulated
with SLE-Associated Immune Complexes.
Olof Berggren, Andrei Alexsson,
Karolina Tandre, Ann-Christine Syvänen,
Lars Rönnblom, Maija-Leena Eloranta
PP262 A new method to evaluate the extent of pulmonary fibrosis in patients with
Systemic sclerosis.
Evangelia Roubi, Sven Nyrén,
Lena Björnådal, Elisabet Svenungsson,
Annica Nordin
PP263 Characterization of histidyl-tRNA
synthetase specific Th cell response in
blood and bronchoalveolar lavage (BAL)
cells of myositis patients.
Inka Albrecht, Eddie James, Maryam Fathi,
Maryam Dastmalchi, Jessica Herrath,
39
Scandinavian Congress of Rheumatology 2014. 20–23 September 2014 Stockholm Sweden
Karine Chemin, Jan Wahlström, Johan
Grunewald, Vivianne Malmström, Ingrid
Lundberg
PP264 Diagnostic Value of ANA and ENA
Among Patients with Paraneoplastic Rheumatic Syndromes.
Giedré Kapleryté, Rita Rugiene, Jolanta
Dadoniene, Eduardas Aleknavicius, Jorg
Distler, Algirdas Venalis, Paulius Venalis
PP265 An uncommon Cause for Dyspnoe.
Beate Fiene, Michael Fiene
PP266 Epilepsy in Systemic lupus erythematosus (SLE).
Liisa Hopia, Magnus Andersson,
Elisabet Svenungsson, Fredrik Piehl,
Torbjörn Tomson
Adolescent rheumatology
PP269 Bone Mineral Density and Predictors Thereof in a Population Based Cohort
of Individuals with Juvenile Chronic Arthritis 17 Years after Disease Onset.
Lennart Bertilsson, Boel Andersson Gäre,
Anders Fasth, Ingemar F Petersson,
Helena Forsblad-d’Elia
PP270 Socioeconomic Consequences of
Juvenile Chronic Arthritis; A PopulationBased Study 22 Years after Disease Onset.
Lennart Bertilsson, Boel Andersson Gäre,
Anders Fasth, Ingemar F Petersson,
Helena Forsblad-d’Elia
PP267 Proteomics and metabolomics in
the classification of SLE subsets.
Per-Johan Jakobsson, Elisabet Svenungsson, Helena Idborg, Peter Nilsson, Craig
Wheelock, Iva Gunnarsson, Johan Trygg,
Janne Lehtiö, Ina Schuppe Koistinen and
“Identification of sub-phenotypes and
biomarkers in systemic autoimmune diseases”, an academic Karolinska-AstraZeneca joint program.
PP268 Renal Microangiopathy in SLE
with Renal Involvement – a Biopsy Study.
Jakob Gerhardsson, Birgitta Sundelin,
Leonid Padyukov, Agneta Zickert, Elisabet
Svenungsson, Iva Gunnarsson
40
www.scr2014.se
Pfi
ze
sy r-s
m po
po n
si so
um re
d
22nd September, 17.00–18.00
Congress Hall A,
Stockholm City Conference Centre, Sweden
Aspects of axial SpA
Deep dive into the key data
on prevalence, diagnosis and
management of the disease
17.00
Welcome and introduction
Professor Lennart Jacobsson (Sweden)
17.05
Axial SpA in Sweden: Prevalence, co-morbidities
and patient-reported outcomes
Professor Lennart Jacobsson
17.20
Therapies for non-radiographic axial SpA:
From clinical trials to clinical practice
Professor Maxime Dougados (France)
17.40
MRI in the non-radiographic axial SpA patient
Associate Professor Lars Erik Kristensen (Sweden)
17.55
Questions and closing remarks
Professor Lennart Jacobsson
Date of preparation: September 2014
ENB20140819PSE01
Chair: Professor Lennart Jacobsson
A programme funded and sponsored by Pfizer. Inc. All rights reserved.
SCANDINAVIAN CONGRESS OF RHEUMATOLOGY [SCR] 2014
20-23 SEPTEMBER 2014 | Stockholm | Sweden
Gold Sponsors
Silver Sponsors